Revvity downgraded by UBS with a new price target
$RVTY
Biotechnology: Laboratory Analytical Instruments
Industrials
UBS downgraded Revvity from Buy to Neutral and set a new price target of $125.00 from $105.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2024 | $125.00 → $140.00 | Equal Weight → Overweight | Barclays |
| 8/28/2024 | $130.00 | Equal Weight | Wells Fargo |
| 7/8/2024 | $125.00 | Outperform | Leerink Partners |
| 6/3/2024 | $115.00 | Hold | Jefferies |
| 1/16/2024 | $105.00 → $125.00 | Buy → Neutral | UBS |
| 1/4/2024 | $88.00 → $125.00 | In-line → Outperform | Evercore ISI |
| 12/19/2023 | $95.00 | Equal Weight | Wells Fargo |
| 12/13/2023 | Peer Perform | Wolfe Research |
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
10-Q - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
10-Q - REVVITY, INC. (0000031791) (Filer)
Revvity, Inc. (NYSE:RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England's renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fields. A cornerstone of the collaboration is the Generation Study, a world-leading study led by Genomics England, in partnership with the National Health Service, that aims to screen up to 100,000 newborns for 200 rare genetic condit
The TotalSeq Phenocyte solution supports robust study of cellular heterogeneity and rare cell types in complex samples at a single cell level Scale Biosciences (Scale BioTM), a leader in innovative and scalable single cell analysis solutions, and Revvity's (NYSE:RVTY) BioLegend business, a leading provider of world-class biological reagents and tools, today announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports customers by more easily identifying and characterizing rare cell subtypes, which ultimately powers immunology and oncology research. The solution is enabled by the proprietary combination of Scale Bioscien
Revvity, Inc. (NYSE:RVTY), will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL. Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here. A live audio webcast will be available on the Events section of the Company's website. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and will be available for at least 30 days. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies
Leerink Partners initiates coverage on Revvity (NYSE:RVTY) with a Outperform rating and announces Price Target of $125.
Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and lowers the price target from $116 to $115.
Baird analyst Catherine Ramsey maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $126 to $127.
Barclays upgraded Revvity from Equal Weight to Overweight and set a new price target of $140.00 from $125.00 previously
Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $130.00
Leerink Partners initiated coverage of Revvity with a rating of Outperform and set a new price target of $125.00
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G - REVVITY, INC. (0000031791) (Subject)
Revvity, Inc. (NYSE:RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England's renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fields. A cornerstone of the collaboration is the Generation Study, a world-leading study led by Genomics England, in partnership with the National Health Service, that aims to screen up to 100,000 newborns for 200 rare genetic condit
Revvity, Inc. (NYSE:RVTY), today announced it will host an Investor Day on Thursday, November 21, 2024 at 9:00 a.m. PT which will feature presentations by members of Revvity's senior management team on the Company's key business initiatives, operational achievements and future financial outlook. The Company also announced strategic adjustments to its operating model to unlock the full value of its recent transformation which will be highlighted at the upcoming Investor Day. Effective fiscal year 2025 (starting December 30, 2024), the majority of Revvity's Applied Genomics business will be integrated into a newly formed Life Sciences Solutions business, encompassing all Life Sciences reage
Revenue of $684 million; 2% reported growth; 2% organic growth GAAP EPS of $0.77; Adjusted EPS from continuing operations of $1.28 Raises full year 2024 adjusted EPS guidance Authorizes new $1 billion share repurchase program To host Investor Day on November 21st Revvity, Inc. (NYSE:RVTY), today reported financial results for the third quarter ended September 29, 2024. The Company reported GAAP earnings per share of $0.77, as compared to $0.08 in the same period a year ago. GAAP revenue for the quarter was $684 million, as compared to $671 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $98 million, as compared to $69 m